TD Cowen raises target for Regeneron stock to USD 980
Published on 10/22/2026 at 11:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSTarget revisions and operating data
- TD Cowen lifted its Regeneron target from USD 960.00 to USD 980.00 on October 21, 2026.
- Second-quarter revenue reached USD 4.29 billion, up 16.70 percent year over year.
- Regeneron stock traded at EUR 715.30 at 11:01 a.m. CEST at Lang & Schwarz on October 22, 2026, 0.10 percent above the Xetra close of October 21, 2026.
Regeneron Pharmaceuticals (ISIN US75886F1075) was trading at EUR 715.30 at Lang & Schwarz on October 22, 2026 at 11:01 a.m. CEST, 0.10 percent above the Xetra close of October 21, 2026. The latest catalyst is a higher analyst target ahead of the company's third-quarter results.
TD Cowen sets USD 980 target
TD Cowen raised its Regeneron price target to USD 980.00 from USD 960.00 on October 21, 2026, while keeping a Buy rating, Markets Insider reported. The firm cited higher expected Eylea franchise sales and a more favorable mix toward Eylea HD.
Revenue reached USD 4.29 billion
Regeneron reported USD 4.29 billion in second-quarter revenue, up 16.70 percent from the same quarter a year earlier, according to MarketBeat. Diluted earnings per share were USD 14.29, above the USD 10.16 consensus estimate for the quarter ended June 30, 2026.
Three dated milestones
On October 12, 2026, Regeneron reported zero new heterotopic ossification lesions for Pasatru patients versus nine for placebo in the OPTIMA extension, according to the Regeneron investor page. On October 15, 2026, an Aktiencheck analysis cited a USD 860.00 chart target. On October 21, 2026, TD Cowen moved its target from USD 960.00 to USD 980.00.
What does the target change mean?
The revision places the analyst target above the current euro quotation, but the currencies are different and do not form a direct upside calculation. Regeneron's second-quarter operating profit was USD 1.29 billion and its operating margin was 30.00 percent, compared with USD 642.90 million and 18.00 percent in the first quarter of 2026.
Upcoming reporting dates
MarketWatch lists October 30, 2026 as the next reporting date for third-quarter results and January 29, 2027 for the full-year 2026 earnings report. The October release will test whether the Eylea mix and recent clinical updates support the higher analyst view.
Stock stays below its yearly high
Regeneron stock was trading at EUR 715.30 at Lang & Schwarz on October 22, 2026 at 11:01 a.m. CEST, 0.10 percent above the Xetra close of October 21, 2026 at EUR 714.60. The euro quotation sits within a 52-week range of EUR 493.90 to EUR 738.20, while the market capitalization was USD 83.0 billion as of October 22, 2026.
The further course of trading is shown by the continuously updated real-time quote of Regeneron stock.
Regeneron stock key data
- Company: Regeneron Pharmaceuticals, Inc.
- ISIN: US75886F1075
- Ticker: REGN
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 22, 2026, 11:01 a.m. CEST): EUR 715.30
- Change versus Xetra close: plus 0.10 percent
- Xetra close (October 21, 2026): EUR 714.60
- Market capitalization: USD 83.0 billion (as of October 22, 2026)
- 52-week range: EUR 493.90-EUR 738.20 (as of October 22, 2026)
- Sector / Industry: Healthcare / Biotechnology
- Next earnings date: October 30, 2026
Market context: Market report Nasdaq Composite.
